School of Medicine
Showing 71-80 of 166 Results
-
Gary M. Shaw
Rosemarie Hess Professor and Professor (Research), by courtesy, of Epidemiology and Population Health and of Obstetrics and Gynecology (Maternal Fetal Medicine)
Current Research and Scholarly InterestsPrimary research interests include 1) epidemiology of birth defects, 2) gene-environment approaches to perinatal outcomes, and 3) nutrition and reproductive outcomes.
-
Xinshu She
Clinical Associate Professor, Pediatrics
Current Research and Scholarly InterestsMy current interests include global mental health promotion in underserved pediatric populations, including refugee health in US-Mexico borders, minority mental health in the US, and parental mental health in low-middle-income countries. I am also interested in physician wellness and Diversity and Inclusion.
-
Hiroyuki Shimada
Professor of Pathology and, by courtesy, of Pediatrics
BioHiroyuki Shimada, MD, PhD, FRCPA (Hon), is Professor of Pathology and of Pediatrics at the Stanford University Medical Center. He was born in Tokyo, Japan, and completed MD (1973) and PhD (1982) at the Yokohama City University School of Medicine, Yokohama, Japan, and also completed his pathology training at the Children's Hospital (now the Nationwide Children’s Hospital) and the Ohio State University, Columbus, Ohio, USA (1988). Before moving to the Stanford University in 2019, he was Professor of Pathology (Clinical Scholar) at the University of Southern California Keck School of Medicine and working at the Children’s Hospital Los Angeles.
Dr. Shimada was Chair of the International Neuroblastoma Pathology Committee (1999-2017) and the founder of the International Neuroblastoma Pathology Classification (INPC). As Director of the COG (Children’s Oncology Group) Neuroblastoma Pathology Reference Laboratory (since 2001), he has been actively reviewing pathology samples of ~700 neuroblastoma cases per year from United States, Canada, Australia, and New Zealand. Pathology review results according to the INPC have been providing critical information for patient stratification and protocol assignment in the COG international neuroblastoma clinical trials.
